rmdopen.bmj5d
Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives
The therapeutic window of opportunity in rheumatoid arthritis (RA) is often referred to. However, some have questioned whether such a period, in which the disease is more susceptible to ...
rmdopen.bmj13d
Mixed connective tissue disease: state of the art on clinical practice guidelines
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic ...
rmdopen.bmj9d
Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study
Background Although genome-wide association studies (GWASs) have identified more than 100 loci associated with rheumatoid arthritis (RA) susceptibility, the causal genes and biological mechanisms ...
rmdopen.bmj11d
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins
Objective Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We ...
rmdopen.bmj4d
Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis
Background Fibromyalgia (FM) is a complex disorder with widespread pain and emotional distress, posing diagnostic challenges. FM patients show altered cognitive and emotional processing, with a ...
rmdopen.bmj8d
Association between musculoskeletal sonographic features and response to treatment in patients with psoriatic arthritis
Objective To investigate the association between musculoskeletal sonographic features and clinical features, as well as treatment outcomes, in patients with active psoriatic arthritis (PsA). Methods A ...
rmdopen.bmj12d
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to ...
rmdopen.bmj13d
Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis
Background Ankylosing spondylitis (AS) is a complex chronic inflammatory disease strongly associated with the majority of human leucocyte antigen (HLA)-B27 alleles. HLA-E molecules are non-classical ...
rmdopen.bmj3d
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort
Background Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the ...
rmdopen.bmj8d
Physical workload is associated with increased risk of rheumatoid arthritis: results from a Swedish population-based case–control study
Objectives This study investigated: (1) the association of physical workload (PW) and risk of rheumatoid arthritis (RA); (2) the potential interactions between PW and the genes in the human leucocyte ...
rmdopen.bmj7d
Synovial fibroblasts in 2017
Stromal cells like synovial fibroblasts gained great interest over the years, since it has become clear that they strongly influence their environment and neighbouring cells. The current review ...
rmdopen.bmj7d
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
Objective To analyse the treatment outcome of patients with ankylosing spondylitis (AS) in the European AS infliximab cohort (EASIC) study after a total period of 8 years with specific focus on dosage ...